Mirati Therapeutics, Inc.
MRTX
Rangering i aksjer
#4928
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Aksjekurs
$58.70
Sist synkronisert: 2024-01-23
Markedsverdi
$2.98B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Mirati Therapeutics, Inc. (MRTX)
Kategori
Healthcare
Historikk for aksjesplitt for Mirati Therapeutics, Inc. (MRTX)
Aksjen Mirati Therapeutics, Inc. (symbol: MRTX) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én MRTX-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 MRTX-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én MRTX-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 MRTX-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
